Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T10430 Eye Drops in Paediatric Myopia Progression
NCT07522242Phase 2Recruiting
- Sponsor
- Laboratoires Théa
- Start
- Jan 2026
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of sodium phenylbutyrate in myopia (4 arms), sponsored by Laboratoires Théa. Primary endpoint: Treatment-Emergent Adverse Events up to 60 weeks. Started Jan 2026; status: recruiting.
02
Drugs
sodium phenylbutyrate
03
Conditions
myopia
Beyond the preview
Go deeper on NCT07522242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07522242.